/CMPX
CMPX Stock - Compass Therapeutics, Inc.
Healthcare|BiotechnologyNASDAQ
$4.99-0.99%
$0.05 (-0.99%) • Dec 19
82
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
High Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.94
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.70
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+100.4%upside
Target: $10.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for CMPX
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$4.94 – $5.04
TARGET (TP)$10.00
STOP LOSS$4.59
RISK/REWARD1:12.5
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.25
52W High$5.86
52W Low$1.33
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $850,000 | N/A | N/A | N/A | N/A |
| Gross Profit | $850,000 | N/A | N/A | N/A | N/A |
| Gross Margin | 100.0% | N/A | N/A | N/A | N/A |
| Operating Income | $-56,625,000 | $-50,363,000 | $-41,655,000 | $-81,882,000 | $-27,812,000 |
| Net Income | $-49,375,000 | $-42,494,000 | $-39,225,000 | $-82,181,000 | $-29,500,000 |
| Net Margin | -5808.8% | N/A | N/A | N/A | N/A |
| EPS | $-0.36 | $-0.33 | $-0.35 | $-1.31 | $-0.52 |
Company Overview
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases. The company's product candidates in the clinical stage of development include CTX-009, an investigational bispecific antibody that blocks Delta-like ligand 4/Notch and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137. Its product candidates also comprise CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1. The company was founded in 2014 and is headquartered in Boston, Massachusetts.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
10
100%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
10 Bullish0 Neutral/Bearish
Price Targets
$11
Average Target
↑ 115.4% Upside
Now
$4
Low
$11
Average
$32
High
Based on 12 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 3rd 2025 | Citizens JMP | Initiation | Mkt Outperform | $10 |
| December 3rd 2025 | Canaccord Genuity | Initiation | Buy | $10 |
| December 3rd 2025 | Cantor Fitzgerald | Initiation | Overweight | - |
| July 1st 2025 | Raymond James | Resumed | Outperform | $9 |
| April 2nd 2025 | Leerink Partners | Upgrade | Outperform | $6 |
| February 24th 2025 | Guggenheim | Initiation | Buy | $12 |
| February 19th 2025 | Piper Sandler | Initiation | Overweight | $12 |
| December 23rd 2024 | D. Boral Capital | Initiation | Buy | $32 |
| November 15th 2024 | Leerink Partners | Downgrade | Market Perform | $4← $5 |
| September 16th 2024 | Ladenburg Thalmann | Upgrade | Buy | $5 |
| January 31st 2023 | Jefferies | Initiation | Buy | $8 |
| January 27th 2023 | Stifel | Initiation | Buy | $9 |
| May 23rd 2022 | H.C. Wainwright | Resumed | Buy | $12 |
Earnings History & Surprises
CMPXBeat Rate
53%
Last 17 quarters
Avg Surprise
+4.8%
EPS vs Estimate
Beats / Misses
9/6
2 met exactly
Latest EPS
$-0.08
Q4 2025
EPS Surprise History
Q1 24
-22.2%
$-0.11vs$-0.09
Q2 24
+27.3%
$-0.08vs$-0.11
Q3 24
0.0%
$-0.10vs$-0.10
Q4 24
+27.3%
$-0.08vs$-0.11
Q1 25
-10.0%
$-0.11vs$-0.10
Q2 25
0.0%
$-0.12vs$-0.12
Q3 25
-7.7%
$-0.14vs$-0.13
Q4 25
+42.9%
$-0.08vs$-0.14
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 6, 2026 | — | — | — | — |
Q1 2026 | Feb 26, 2026 | $-0.10 | — | — | — |
Q4 2025 | Nov 5, 2025 | $-0.14 | $-0.08 | +42.9% | ✓ BEAT |
Q3 2025 | Aug 11, 2025 | $-0.13 | $-0.14 | -7.7% | ✗ MISS |
Q2 2025 | May 8, 2025 | $-0.12 | $-0.12 | 0.0% | = MET |
Q1 2025 | Feb 27, 2025 | $-0.10 | $-0.11 | -10.0% | ✗ MISS |
Q4 2024 | Nov 12, 2024 | $-0.11 | $-0.08 | +27.3% | ✓ BEAT |
Q3 2024 | Aug 12, 2024 | $-0.10 | $-0.10 | 0.0% | = MET |
Q2 2024 | May 13, 2024 | $-0.11 | $-0.08 | +27.3% | ✓ BEAT |
Q1 2024 | Mar 21, 2024 | $-0.09 | $-0.11 | -22.2% | ✗ MISS |
Q4 2023 | Nov 9, 2023 | $-0.11 | $-0.08 | +27.3% | ✓ BEAT |
Q3 2023 | Aug 3, 2023 | $-0.08 | $-0.09 | -12.5% | ✗ MISS |
Q2 2023 | May 4, 2023 | $-0.11 | $-0.06 | +45.5% | ✓ BEAT |
Q1 2023 | Mar 15, 2023 | $-0.11 | $-0.10 | +9.1% | ✓ BEAT |
Q4 2022 | Nov 9, 2022 | $-0.11 | $-0.12 | -9.1% | ✗ MISS |
Q3 2022 | Aug 1, 2022 | $-0.09 | $-0.08 | +11.1% | ✓ BEAT |
Q2 2022 | May 9, 2022 | $-0.14 | $-0.07 | +50.0% | ✓ BEAT |
Q1 2022 | Mar 21, 2022 | $-0.07 | $-0.15 | -114.3% | ✗ MISS |
Q4 2021 | Nov 12, 2021 | $-0.12 | $-0.10 | +16.7% | ✓ BEAT |
Q3 2021 | Aug 16, 2021 | — | $-1.07 | — | — |
Latest News
Cantor Fitzgerald Initiates Coverage On Compass Therapeutics with Overweight Rating
📈 PositiveBenzinga•Dec 3, 2025, 04:11 PM
Citizens Initiates Coverage On Compass Therapeutics with Market Outperform Rating, Announces Price Target of $10
📈 PositiveBenzinga•Dec 3, 2025, 03:46 PM
Canaccord Genuity Initiates Coverage On Compass Therapeutics with Buy Rating, Announces Price Target of $10
📈 PositiveBenzinga•Dec 3, 2025, 12:35 PM•Also:
Compass Therapeutics Q3 EPS $(0.08) Beats $(0.14) Estimate
📈 PositiveBenzinga•Nov 5, 2025, 12:34 PM
Compass Therapeutics To Present Preclinical CTX-10726 Data At Society for Immunotherapy of Cancer Annual Meeting Nov. 7
➖ NeutralBenzinga•Nov 4, 2025, 02:04 PM
Compass Therapeutics dips 5%, prices $120M stock
📉 NegativeSeeking Alpha•Aug 13, 2025, 05:48 AM
Compass Therapeutics rises after pipeline updates
📈 PositiveSeeking Alpha•Aug 11, 2025, 05:55 PM
Compass Therapeutics Posts Wider Q2 Loss
📉 NegativeThe Motley Fool•Aug 11, 2025, 11:12 AM
Frequently Asked Questions about CMPX
What is CMPX's current stock price?
Compass Therapeutics, Inc. (CMPX) is currently trading at $4.99 per share. The stock has moved -0.99% today.
What is the analyst price target for CMPX?
The average analyst price target for CMPX is $10.00, based on 1 analyst.
What sector is Compass Therapeutics, Inc. in?
Compass Therapeutics, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is CMPX's market cap?
Compass Therapeutics, Inc. has a market capitalization of $0.69 billion, making it a small-cap company.
Does CMPX pay dividends?
No, Compass Therapeutics, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorBCYC
Bicycle Therapeutics plc
$6.87
Mkt Cap: $0.5B
CRVS
Corvus Pharmaceuticals, Inc.
$7.49
Mkt Cap: $0.6B
FDMT
4D Molecular Therapeutics, Inc.
$8.68
Mkt Cap: $0.4B
FULC
Fulcrum Therapeutics, Inc.
$12.28
Mkt Cap: $0.7B
GOSS
Gossamer Bio, Inc.
$3.44
Mkt Cap: $0.8B
KALV
KalVista Pharmaceuticals, Inc.
$15.23
Mkt Cap: $0.8B
LXRX
Lexicon Pharmaceuticals, Inc.
$1.17
Mkt Cap: $0.4B
MNPR
Monopar Therapeutics Inc.
$68.63
Mkt Cap: $0.5B
OCGN
Ocugen, Inc.
$1.40
Mkt Cap: $0.4B
OMER
Omeros Corporation
$9.60
Mkt Cap: $0.7B
Explore stocks similar to CMPX for comparison